Adjuvants

Making Vaccines Immunogenic

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.

Original languageEnglish (US)
Title of host publicationVaccinology: An Essential Guide
PublisherWiley Blackwell
Pages93-108
Number of pages16
ISBN (Electronic)9781118638033
ISBN (Print)9780470656167
DOIs
StatePublished - Dec 9 2014

Fingerprint

Vaccines
Antigens
European Union
Recombinant Proteins
Safety
Proteins

Keywords

  • Adjuvants
  • Alum
  • Antigens
  • Emulsion
  • Human vaccines
  • Pathogen recognition receptors
  • Pathogen-associated molecular patterns
  • Reactogenicity
  • Veterinary vaccines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Milligan, G. (2014). Adjuvants: Making Vaccines Immunogenic. In Vaccinology: An Essential Guide (pp. 93-108). Wiley Blackwell. https://doi.org/10.1002/9781118638033.ch6

Adjuvants : Making Vaccines Immunogenic. / Milligan, Gregg.

Vaccinology: An Essential Guide. Wiley Blackwell, 2014. p. 93-108.

Research output: Chapter in Book/Report/Conference proceedingChapter

Milligan, G 2014, Adjuvants: Making Vaccines Immunogenic. in Vaccinology: An Essential Guide. Wiley Blackwell, pp. 93-108. https://doi.org/10.1002/9781118638033.ch6
Milligan G. Adjuvants: Making Vaccines Immunogenic. In Vaccinology: An Essential Guide. Wiley Blackwell. 2014. p. 93-108 https://doi.org/10.1002/9781118638033.ch6
Milligan, Gregg. / Adjuvants : Making Vaccines Immunogenic. Vaccinology: An Essential Guide. Wiley Blackwell, 2014. pp. 93-108
@inbook{596d1a2839e54eecb610dd9addd52297,
title = "Adjuvants: Making Vaccines Immunogenic",
abstract = "The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.",
keywords = "Adjuvants, Alum, Antigens, Emulsion, Human vaccines, Pathogen recognition receptors, Pathogen-associated molecular patterns, Reactogenicity, Veterinary vaccines",
author = "Gregg Milligan",
year = "2014",
month = "12",
day = "9",
doi = "10.1002/9781118638033.ch6",
language = "English (US)",
isbn = "9780470656167",
pages = "93--108",
booktitle = "Vaccinology: An Essential Guide",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Adjuvants

T2 - Making Vaccines Immunogenic

AU - Milligan, Gregg

PY - 2014/12/9

Y1 - 2014/12/9

N2 - The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.

AB - The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.

KW - Adjuvants

KW - Alum

KW - Antigens

KW - Emulsion

KW - Human vaccines

KW - Pathogen recognition receptors

KW - Pathogen-associated molecular patterns

KW - Reactogenicity

KW - Veterinary vaccines

UR - http://www.scopus.com/inward/record.url?scp=84976417314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976417314&partnerID=8YFLogxK

U2 - 10.1002/9781118638033.ch6

DO - 10.1002/9781118638033.ch6

M3 - Chapter

SN - 9780470656167

SP - 93

EP - 108

BT - Vaccinology: An Essential Guide

PB - Wiley Blackwell

ER -